Catalepsy
Catalepsy (from Ancient Greek katálēpsis, κατάληψις, “seizing, grasping”) is a nervous condition characterized by muscular rigidity and fixity of posture regardless of external stimuli, as well as decreased sensitivity to pain.
Cluster Number:
Wiki Number: W035
Diagnosis: Catalepsy
US Patients:
World Patients:
Sex Ratio:
Age Onset:
Brain Area:
Symptoms: muscular rigidy and increased pain; slowing of bodily functions, such as breathing
Progression: Shakespeare used it in “Romeo and Juliet.” Other authors have described people thought to be dead instead.
Causes: varies: cocaine withdrawal, reaction to drugs to treat schizophrenia
Medications: None described.
Therapies: None described.
Amazon or Library Book: On the Curability of Certain Forms of Insanity, Epilepsy, Catalepsy, and Hysteria in Females
Click the book to link or order from Amazon.
4 CURRENT ARTICLES
FROM PUBMED
The world-wide medical research
reports chosen for each diagnosis
Clicking each title opens the
PubMed article’s summary-abstract.
- Catatonia in an acute adult inpatient population in mental health units in Khartoum, Sudan: A cross-sectional studyby Maysoon B Idrees on March 20, 2025
CONCLUSION: Catatonic syndrome is highly prevalent in an acute psychiatric inpatient population in Sudan regardless of age or sex. Echopraxia/echolalia (84.5%) and mutism were the main manifestations among the patients with catatonic syndrome.
- G-Protein-Coupled Estrogen Receptor 1 (GPER1) Activation Mitigates Haloperidol-Induced Neurotoxicity in SHSY-5Y Cells and Improves Motor Functions in Adult Zebrafishby Shubham Upadhayay on March 15, 2025
Haloperidol (Halo) is a typical antipsychotic medication used to treat schizophrenia, but its long-term treatment causes neurotoxicity, leading to irregular involuntary movements called Tardive Dyskinesia. Raloxifene (Ralo) and fulvestrant (Fulve) are G-protein-coupled estrogen receptor 1 (GPER1) activators and show similar pharmacological properties as identified in 17β-estradiol. It is reported to have anti-oxidant, anti-inflammatory, and anti-apoptotic properties against neurological...
- A2A Adenosine Receptor Antagonists and Their Efficacy in Rat Models of Parkinson's Diseaseby Andrea Spinaci on March 12, 2025
Parkinson's disease (PD) represents a growing challenge to global health, as it involves millions of people. The high grade of disability is due to the loss of dopaminergic neuron activity, and levodopa is the gold-standard therapy used to restore dopamine in the dopamine-denervated regions. Another therapeutic approach is the use of A(2A) adenosine receptor antagonists and, among them, istradefylline is the only one currently approved for therapy in association with levodopa. In this work, we...
- Virtual library docking for cannabinoid-1 receptor agonists with reduced side effectsby Tia A Tummino on March 5, 2025
Virtual library docking can reveal unexpected chemotypes that complement the structures of biological targets. Seeking agonists for the cannabinoid-1 receptor (CB1R), we dock 74 million tangible molecules and prioritize 46 high ranking ones for de novo synthesis and testing. Nine are active by radioligand competition, a 20% hit-rate. Structure-based optimization of one of the most potent of these (K(i) = 0.7 µM) leads to '1350, a 0.95 nM ligand and a full CB1R agonist of G(i/o) signaling. A...